HBx protein-mediated ATOH1 downregulation suppresses ARID2 expression and promotes hepatocellular carcinoma

Area of Science:

• Hepatology
• Molecular Biology
• Oncology

Background:

• Hepatocellular carcinoma (HCC) is a major global health concern, often linked to Hepatitis B virus (HBV) infection.
• The HBV X protein (HBx) is implicated in HCC pathogenesis.
• ARID2 is a known tumor suppressor that inhibits hepatoma cell growth.

Purpose of the Study:

• To investigate the role of HBx in modulating ARID2 expression.
• To elucidate the molecular mechanisms by which HBx influences ARID2.
• To determine the functional significance of the HBx-ARID2 interaction in HBV-related hepatocarcinogenesis.

Main Methods:

• Analysis of ARID2 expression in HBV-replicative cells, HBV transgenic mice, and clinical HCC tissues.
• Correlation analysis between HBx and ARID2 levels in HCC tissues.
• Reporter assays to assess transcriptional regulation of ARID2 by HBx.
• Investigation of the role of ATOH1 binding elements in the ARID2 promoter.
• Functional assays evaluating the impact of ARID2 and ATOH1 on hepatoma cell migration, proliferation, and tumorigenicity.

Main Results:

• ARID2 expression was significantly downregulated in HBV-infected contexts and negatively correlated with HBx levels in HCC.
• HBx suppressed ARID2 transcription, with the effect localized to a promoter region containing ATOH1 binding sites.
• Ectopic ATOH1 expression or disruption of ATOH1 binding sites partially rescued HBx-induced ARID2 repression.
• ARID2 counteracted HBx-driven hepatoma cell migration and proliferation, while ATOH1 depletion enhanced HCC cell tumorigenicity.

Conclusions:

• HBx downregulates ARID2 expression at the transcriptional level, potentially through interaction with ATOH1.
• This deregulation of ARID2 by HBx contributes to the development of HBV-related hepatocellular carcinoma.
• Targeting the HBx-ARID2-ATOH1 pathway may offer therapeutic strategies for HCC.